Download PDF
Thromb Haemost 2001; 86(06): 1583-1584
DOI: 10.1055/s-0037-1616769
Letters to the Editor
Schattauer GmbH

Ala147Thr and C+1542G Polymorphisms in the TAFI Gene Are not Asssociated with a Higher Risk of Venous Thrombosis in FV Leiden Carriers

P. E. Morange
1   Laboratoire d‘Hématologie, INSERM EPI 99-36, Marseille, France
,
M. F. Aillaud
1   Laboratoire d‘Hématologie, INSERM EPI 99-36, Marseille, France
,
V. Nicaud
2   INSERM U525, Paris, France
,
M. Henry
1   Laboratoire d‘Hématologie, INSERM EPI 99-36, Marseille, France
,
I. Juhan-Vague
1   Laboratoire d‘Hématologie, INSERM EPI 99-36, Marseille, France
› Author Affiliations
Further Information

Publication History

Received 26 February 2001

Accepted after resubmission 12 September 2001

Publication Date:
12 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
    CrossrefPubMedGoogle Scholar
  • 2 Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-100.
    PubMedGoogle Scholar
  • 3 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
    CrossrefPubMedGoogle Scholar
  • 4 Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
    CrossrefPubMedGoogle Scholar
  • 5 Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
    PubMedGoogle Scholar
  • 6 Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20: 2156-61.
    CrossrefPubMedGoogle Scholar
  • 8 Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
    CrossrefPubMedGoogle Scholar
  • 9 Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998; 80: 949-55.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Morange PE, Henry M, Tregouët D, Granel B, Aillaud MF, Alessi MC, Juhan-Vague I. The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in Factor V Leiden carriers. Arterioscl Thromb Vasc Biol 2000; 20: 1387-91.
    CrossrefPubMedGoogle Scholar
  • 11 Trégouët DA, Ducimetière P, Tiret L. Testing association between candidate-gene markers and phenotype in related individuals, by use of estimating equations. Am J Hum Gen 1997; 61: 189-99.
    CrossrefPubMedGoogle Scholar